Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.13	$1.22	$0.85 ▼ $4.40	$36.36M	0.21	31,097 shs	47,264 shs
CPIX Cumberland Pharmaceuticals	$3.22 -13.2%	$4.53	$1.04 ▼ $7.25	$55.51M	-0.39	874,095 shs	143,377 shs
FWP Forward Pharma A/S	$1.95	$2.17	$1.50 ▼ $6.48	$13.83M	1.38	7,484 shs	N/A
RGLS Regulus Therapeutics	$8.16	$8.07	$0.83 ▼ $8.35	$564.92M	0.35	1.01 million shs	N/A
SNGX Soligenix	$1.36	$1.66	$1.09 ▼ $6.36	$4.44M	1.87	344,549 shs	246,296 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+1.80%	-1.31%	-4.24%	-6.15%	-70.50%
CPIX Cumberland Pharmaceuticals	-4.38%	+11.08%	-31.30%	-22.06%	+152.38%
FWP Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
RGLS Regulus Therapeutics	0.00%	0.00%	-0.49%	+296.12%	+380.00%
SNGX Soligenix	+2.26%	+7.09%	-24.02%	-35.24%	-80.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	2.7868 of 5 stars	3.5	3.0	0.0	0.0	2.2	3.3	0.0
CPIX Cumberland Pharmaceuticals	0.8866 of 5 stars	0.0	5.0	0.0	0.0	1.6	1.7	0.0
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	1.6644 of 5 stars	2.1	5.0	0.0	0.0	0.6	3.3	0.0
SNGX Soligenix	2.5958 of 5 stars	3.5	3.0	0.0	0.0	2.4	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	342.48% Upside
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
FWP Forward Pharma A/S	0.00	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside
SNGX Soligenix	3.00	Buy	$6.00	341.18% Upside

Current Analyst Ratings Breakdown

Latest SNGX, FWP, CPIX, RGLS, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/16/2025	SNGX Soligenix	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $6.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
CPIX Cumberland Pharmaceuticals	$37.87M	1.27	$0.22 per share	14.42	$1.61 per share	2.00
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	$10.09 per share	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
SNGX Soligenix	$120K	36.95	N/A	N/A	$1.64 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-213.59%	-65.60%	8/18/2025 (Estimated)
CPIX Cumberland Pharmaceuticals	-$6.48M	-$0.25	41.22	∞	N/A	-7.98%	6.92%	2.33%	8/5/2025 (Estimated)
FWP Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)
SNGX Soligenix	-$8.27M	-$4.29	0.00	N/A	N/A	N/A	-223.89%	-103.50%	8/8/2025 (Estimated)

Latest SNGX, FWP, CPIX, RGLS, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RGLS Regulus Therapeutics	-$0.23	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	SNGX Soligenix	-$0.79	N/A	N/A	N/A	N/A	N/A
5/9/2025	Q1 2025	SNGX Soligenix	-$0.67	-$1.06	-$0.39	-$1.06	N/A	N/A
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/6/2025	Q1 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.15	N/A	$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
SNGX Soligenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.16	0.16
CPIX Cumberland Pharmaceuticals	0.18	1.25	1.09
FWP Forward Pharma A/S	N/A	18.43	N/A
RGLS Regulus Therapeutics	N/A	16.31	16.31
SNGX Soligenix	N/A	1.85	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
CPIX Cumberland Pharmaceuticals	15.51%
FWP Forward Pharma A/S	12.57%
RGLS Regulus Therapeutics	92.38%
SNGX Soligenix	3.60%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
CPIX Cumberland Pharmaceuticals	44.85%
FWP Forward Pharma A/S	71.47%
RGLS Regulus Therapeutics	4.35%
SNGX Soligenix	3.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
CPIX Cumberland Pharmaceuticals	80	14.96 million	8.25 million	Optionable
FWP Forward Pharma A/S	4	7.09 million	2.02 million	Not Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable
SNGX Soligenix	20	3.26 million	3.16 million	Not Optionable

SNGX, FWP, CPIX, RGLS, and AKTX Headlines

Recent News About These Companies

SNGX: Multiple Catalysts Upcoming in 2H25…

July 11, 2025 | finance.yahoo.com

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

July 8, 2025 | prnewswire.com

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - Seeking Alpha

July 3, 2025 | seekingalpha.com

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

July 1, 2025 | prnewswire.com

Soligenix Approves 2025 Equity Incentive Plan at Meeting

June 20, 2025 | tipranks.com

Soligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

June 17, 2025 | theglobeandmail.com

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

June 6, 2025 | finance.yahoo.com

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

June 6, 2025 | globenewswire.com

Soligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

May 24, 2025 | theglobeandmail.com

Soligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

May 20, 2025 | theglobeandmail.com

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…

May 13, 2025 | finance.yahoo.com

SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025 | finanznachrichten.de

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025 | prnewswire.com

Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode

May 7, 2025 | theglobeandmail.com

Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode

May 7, 2025 | theglobeandmail.com

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.

May 7, 2025 | finance.yahoo.com

Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

April 30, 2025 | msn.com

Solgenix shares rise on positive skin cancer treatment results

April 24, 2025 | investing.com

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.

April 24, 2025 | msn.com

EQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

April 24, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX, FWP, CPIX, RGLS, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$1.13 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.14 +0.01 (+0.88%)

As of 07:51 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.22 -0.49 (-13.21%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 +0.30 (+9.32%)

As of 07:52 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Forward Pharma A/S NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Soligenix NASDAQ:SNGX

$1.36 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 07:36 PM Eastern

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time